Safety and effectiveness of risedronate in Paget ’s disease of bone: postmarketing surveillance study in Japan
ConclusionTo conclude, risedronate 17.5 mg/day is safe and effective for treating patients with PDB in daily practice.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
More News: Actonel | Drugs & Pharmacology | Gastroenterology | Japan Health | Orthopaedics | Paget's Disease | Pain | Risedronate | Study